• Revenues down 53.3% to $89,119
• Loss up 1.7% to $1,983,363
• Continued clinical trials in US and Australia
• Progressing patent applications globally

Cleo Diagnostics Limited (ASX:COV) announced its financial results for the half-year ended 31 December 2025. The company reported revenues of $89,119, down 53.3% from the previous corresponding period. The loss for the period was $1,983,363, up 1.7% from the previous year. The current year loss was after receiving $1,717,150 in Research and Development Tax Incentives. During the period, Cleo advanced key initiatives to commercialize its pre-surgical triage test in the US, while also laying the groundwork for broader patient markets, including early-stage screening. The company made notable progress across technology development, manufacturing readiness, clinical trials, market access, and strategic partnerships. Cleo increased the number of active clinical trial sites, continued recruitment for its pivotal US clinical trial, and announced the selection of Bio-Techne's Ella platform as the immunoassay instrument to deliver its ovarian cancer test. The company also acquired biobank samples to support its FDA submission and screening test development. Cleo received positive feedback from the FDA, completed Stage 1 of the Medical Device Single Audit Program, and commenced a health economic study to support its market entry and reimbursement. The company ended the period with $9.4 million in cash and raised an additional $5 million through a placement.